Conflict of interest
Cancer, Tumor, JCP
CANCER, ONCOLOGY, TUMOR, EMD
AJ reports support from NCI R01CA149456, R01DE024371, and P50CA261605. AJ institution has contracts with Cantargia, DebioPharm, Iovance, Khar Biopharma, Merck, Moderna, Pfizer, Sanofi, and SQZ for trials where he is the local PI. JB institution has contracts with Aselias, Exlixis, OPEN Health, Pfizer, Sanofi, Toler, Xencor, Changchun Intellicrown, Synemore, Impact Therapeutics and Nektar. JB also reports stock interests in Forty-seven, Zymeworks, Moderna, Aprea, Merus, and Hylapharm. WTI reports support from an NCCN Young Investigator Award, consulting relationships with Genentech, Jazz Pharma, G1 Therapeutics, Mirati, Bristol Myers Squibb, Takeda, Janssen, EMD Serono, OncLive, Curio Science, Chardan, Cello Health, Outcomes Insights, and Clinical Care Options. WTI - Vanderbilt University Medical Center has contracts with Takeda, Amgen, Nitto Biopharma, Lilly, and Merck for trials where he is the local PI. JCP reports honoraria from Cancer Expert Now and Alira Health; consulting or advisory roles with GC Cells, Selexcine, ABL Bio, BW Biomed, and Mitoimmune; and institutional contracts with ALX Oncology, Inhibrx, Merck, Oncorus, ISA Therapeutics, and Monopteros Therapeutics. MSG has consulting/advisory board relationships with Imaging Endpoints, Instil Bio, Tracon, Daiichi, and Qualigen; patent participation with Caremisson, and institutional contracts with GSK, Abbvie, Merck Serono, Medimmune, Incyte, Pfizer, Amgen, Gilead Sciences, Endocyte, Seattle Genetics, Plexxicon/Daiichi, Celldex, Tracon, Deciphera, Fujifilm, Minnemarita, Nektar, Novita, Biosplice, Corcept, Novartis, Toray, Genzada, Salarius, Agenus, Inhibrx, AADI, Revolution Medicine, Blueprint, Astellas, BioNTech, Helix, IgM Biosciences, ImmuneSensor, Bioeclipse, Bioline, Black Diamond, Codiak, Dracen, Elevation Oncology, Famewave, Forma Therapeutics, IntraImmun SG, Pionyr, Trishula, Tolero, Vedanta Biosciences, Coordination Therapeutics, Ideaya Biosciences, I-Mab, NiKang, Nimbus Therapeutics, OncoResponse, Riboscience, Rubius Therapeutics, Simcha Therapeutics, Siranomics, Synthorx, Theseus Pharmaceuticals, Zai Labs, Genentech/Roche. MT is a consultant or advisory board member to Bristol Myers Squibb, Eisai Inc, Novartis, Merck, Pfizer, Bayer, Sanofi/Genzyme, Regeneron, Bayer, LOXO oncology, Blueprint Medicines, Immune-onc, Exelixis, and Cascade Prodrug; he is on the speakers bureau (honoraria) for Bristol Myers Squibb, Eisai Inc, Blueprint Medicines, and Merck; the Providence Cancer Institute has research agreements with Bristol Myers Squibb, Eisai, Merck, Pfizer, Immune-Onc, and Simcha. ADL reports institutional contracts with Bristol Myers Squibb, Exelixis, Arrys Therapeutics Inc, Hutchison Medipharma Ltd, Corcept Therapeutics, Conjupro Biotherapeutics Inc, and AbbVie for trials where she is the local PI. OY has consultant/advisory relations with GIMV NV, TigaTx Inc, Celldex, and hC Bioscience. He is the local PI under institutional contracts with Ascendis Pharma A/S, Avant Immunotherapeutics, Instil Bio Inc, and Merck Sharp & Dohme Corp. JCM has consulted for BMS, Amunix, Thirona Bio, Adagen, Imaging Endpoints, and Caris Life Sciences. JCM receives compensation as a member of the Caris Molecular Tumor Board, and receives speaker honoraria from Caris Life Sciences and Immunocore. JCM institution has research contracts with Alpine Immune Sciences, Amgen, BioElipse Therapeutics, Fujiilm, Genetech, Ideaya Biosciences, ImmuneSensor, Istari Oncology, Nektar Therapuetics, NovoCure, Repertoire Immune Sciences, Rubius, Simcah, Synthorx Inc, Trishula Therapeutics, and University of Arizona. SML, JJ, NRM, RRJ, RFZ, HB, and AS are employees of SQZ Biotechnologies; in addition to salaried compensation, they may receive stock, stock options, or other incentive remuneration. SML, HB, and AS are among named inventors of patents either licensed by or assigned to SQZ Biotechnologies. MK and NN are employed by Roche which has a partnership with SQZ Biotechnologies. MM, ND, PN, CE, AM, and MB have no disclosures to report.